Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
Studies reveal that oral semaglutide weight loss trials demonstrate a reduced risk of major cardiovascular eventsincluding heart attack and strokein adults with obesity or overweight who have known cardiovascular disease
Percentage of people hitting weight loss goals: Semaglutide: 50% lose 15%+ of body weight Tirzepatide: 63% lose 20%+ of body weight More people achieve significant weight loss with tirzepatide
GLP-1 RAs also improve insulin sensitivity, reduce ectopic fat deposition, and modulate adipose tissue metabolism by stimulating lipolysis and inhibiting lipogenesis [12, 13]
Weekly Convenience The drugs extended half-life allows for simple once-weekly administration
With increasing numbers of patients diagnosed with diabetes, demand for such multi-indication therapy increases, forcing uniform adoption in developing and mature economies as well
